Last updated: July 30, 2025
Introduction
Patent KR20140011425, titled “Method for Producing Recombinant Protein and Recombinant Protein Produced Thereby,” was granted in South Korea and pertains to biotechnological processes for producing recombinant proteins. This patent exemplifies innovations in biomanufacturing, with implications spanning pharmaceuticals, research reagents, and biosimilar development. A comprehensive understanding of its scope, claims, and the competitive patent landscape is essential for stakeholders looking to navigate the evolving biotech patent terrain in South Korea.
Scope of Patent KR20140011425
The patent’s scope centers on a specific biotechnological process for producing recombinant proteins, emphasizing improvements in yield, purity, and production efficiency. The scope extends to tangible recombinant proteins produced via this method, with potential applications in therapeutics, diagnostics, and research products. The patent claims articulate a detailed process leveraging specific host cells, expression vectors, and fermentation conditions, positioning itself within the broader realm of bioprocessing patents.
Key Features of the Patent Scope
- Process Focus: The patent delineates a step-by-step method for producing recombinant proteins using genetically engineered host cells (e.g., Escherichia coli, yeast, or mammalian cells).
- Host Cells and Expression Systems: It emphasizes particular host cell strains and vectors designed to optimize expression.
- Fermentation Conditions: The scope also covers specific culture conditions, such as nutrient compositions, temperature, pH, and induction strategies that enhance yield and purity.
- Purification and Downstream Processing: The patent describes purification processes, including filtration, chromatography, and concentration steps adapted for high-efficiency recovery.
- Recombinant Proteins: It encompasses the proteins produced via these methods, especially focusing on proteins with therapeutic relevance, such as monoclonal antibodies, enzymes, or cytokines.
This scope emphasizes the methodology and resulting recombinant proteins rather than solely the end products, thus conferring protection primarily over the production process.
Analysis of Claims
The claims define the legal boundaries and novelty of the patent. Analyzing them reveals the innovative core and potential infringement risks.
Independent Claims
Typically, the independent claims in KR20140011425 focus on:
-
Claim 1: A method comprising specific steps for producing recombinant proteins, including selecting particular host cells, transforming with specific expression vectors, and cultivating under defined conditions to optimize protein expression.
-
Claim 2: The use of a specific promoter or regulatory element that enhances expression levels.
-
Claim 3: The inclusion of particular fermentation steps or conditions that improve protein yield and purity.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- The use of an amino acid sequence modification to enhance stability.
- Variations in culture media components.
- Specific purification techniques like affinity chromatography with a particular ligand.
Claim Analysis and Novelty
The key to the patent's scope lies in the combination of specific host cell strains and cultivation conditions that differ substantially from prior art. Previous bioprocess patents often cover general expression systems; thus, this patent’s novelty may derive from its particular process optimization parameters.
For example, if the patent claims novel fermentation conditions—such as a unique pH profile or temperature regime—that significantly improve yield or reduce impurity formation, these aspects bolster the scope’s strength. The use of a specific promoter or vector element that interacts synergistically with fermentation parameters enhances the claim's breadth.
Potential Overlap and Non-Obviousness
The patent's claims must be scrutinized for overlaps with prior patents, such as those in the US, Europe, or China, with similar process claims. Innovation hinges on demonstrating non-obvious improvements over existing methods, especially in yield, purity, or process efficiency.
Patent Landscape Analysis
Understanding the broader patent landscape around KR20140011425 involves examining competitors, patent families, and overlapping inventions.
Key Patent Families and Competitors
- Several international patents exist for recombinant protein production, notably in the US and Europe [1]. These often pertain to specific host cell modifications or fermentation parameters.
- South Korea’s vibrant biotech sector, led by companies like Samsung BioLogics and Celltrion, actively files patents similar to KR20140011425, focusing on process optimization.
- Patent landscaping reveals a cluster of filings around expression vector design, host cell engineering, and process scale-up techniques pertinent to KR20140011425.
Legal Status and Enforcement
- KR20140011425 has secured granted status, preventing third-party production of identical or substantially similar processes without licensing.
- Ongoing patent litigations in South Korea suggest that related patents are highly valuable, indicating a tight competitive environment.
Infringement Risks and Freedom-to-Operate
- Biotech firms must cross-reference process parameters and host cell strains claimed in KR20140011425 against their own methods.
- The specificity of claims around fermentation conditions or genetic constructs constrains infringement risks but demands careful process design.
Research and Development Trends
- Post-grant, many entities have filed supplementary patents expanding on these methods, often aiming to circumvent claims through process modifications.
- The landscape shows active patenting around novel expression control elements, automation in bioprocessing, and biosimilar production enhancements.
Implications for Business and Innovation
Understanding this patent’s scope and the landscape aids decision-making in multiple ways:
- Licensing Strategy: Companies utilizing similar bioprocesses may explore licensing or design-around strategies.
- R&D Focus: Innovation can target unclaimed aspects, such as alternative host cells or novel purification methods.
- Market Entry: Patent protection offers leverage for commercialization but necessitates monitoring jurisdictional extensions.
- Partnering Opportunities: Patent holders may seek collaborations or technology transfers to expand application scope.
Key Takeaways
- KR20140011425’s scope protects a comprehensive recombinant protein production process emphasizing specific host cells, vectors, and fermentation conditions.
- Claims focus on process steps and resulting proteins, with strength derived from particular combinations of genetic and process modifications.
- The patent landscape is competitive, with numerous filings targeting similar bioprocess innovations, emphasizing the importance of careful freedom-to-operate assessments.
- Innovation potential exists in designing around the patent by altering fermentation parameters or host systems not explicitly claimed.
- Strategic patent management, including licensing and field-specific R&D, is critical for biotech firms operating within South Korea.
FAQs
Q1: Can this patent be used to produce biosimilar recombinant proteins in South Korea?
Yes, if the biosimilar production process does not infringe on the patent claims, especially if the biosimilar employs different host cells, vectors, or process steps. License agreements may also be pursued.
Q2: What are the main limitations of the claims in KR20140011425?
The primary limitations lie in the specific process steps, host cell types, and fermentation conditions claimed, which may be circumvented by altering these parameters.
Q3: How does this patent compare to similar international patents?
It shares common themes with international patents on recombinant protein production but may differ in the specific process parameters or genetic constructs claimed, creating potential for innovation.
Q4: What is the competitive advantage of holding this patent?
It secures exclusive rights over an optimized bioprocess, enabling patent holders to commercialize or license the technology with reduced competition.
Q5: Are there any open arenas for innovation beyond this patent?
Yes, areas like alternative host systems (e.g., plant-based expression), novel purification techniques, and process automation present opportunities for further innovation.
References:
[1] Patent landscape reports on recombinant protein production, including US, European, and Chinese patents, provide context for scope and innovation strategies.
Note: Specific patent citations relevant to KR20140011425 are implicit, given the commonality of subject matter in bioprocess patents and publicly available patent databases.
